Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor of neurology, Albert Einstein College of Medicine, addresses the treatment of narcolepsy in recent years.
There are several features of narcolepsy that are considered when prescribing treatment, with sodium oxybate currently serving as a first-line treatment in these patient populations, said Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor of neurology, Albert Einstein College of Medicine.
Transcript
Can you speak on current methods of treatment for narcolepsy-related excessive daytime sleepiness and factors considered when prescribing treatment?
For the treatment of narcolepsy, we have quite a large number of medications. There have been a number of new medications that have been approved recently. Traditionally, we had the stimulants, such as amphetamines and methylphenidate, and these are largely sort of going away, as we have drugs and medications that are more specific for the treatment of narcolepsy.
There are many features to narcolepsy, such as excessive daytime sleepiness, abnormal REM [rapid-eye movement] phenomena, and disturbed nocturnal sleep. And the medications that are being used in narcolepsy have targeted either 1 or more of these particular symptoms. Most of the medications that have been used in the past have targeted the excessive daytime sleepiness component of narcolepsy, so they would be more alerting or wake-promoting medications.
With the development of sodium oxybate back in 2000, we really saw medication that could treat all symptoms of narcolepsy. So we could treat the nocturnal sleep disturbance that we typically see in narcolepsy, the excessive daytime sleepiness, and the abnormal REM phenomena, particularly cataplexy. So, oxybate has become really a first-line treatment for patients with narcolepsy.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
What We’re Reading: HHS' Funding Flat; Mifepristone Safety; Insulin Shortage
March 25th 2024Flat funding for Health and Human Services (HHS) leaves critical health initiatives stagnant; Supreme Court weighs tightening regulations on abortion pill; manufacturing delay sparks access concerns for insulin medication.
Read More